{"name":"NexImmune Inc.","slug":"neximmune-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":19282230,"netIncome":-32344393,"cash":3202452,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQUktpTmJHQ1doRDE1STBicXhzM04tUXdzLTlkdzNZV1NVV2U5UEFteEJfR3pORi0zNUoxb3BBSzBjRmVUQ2ZhNHNISzh4MUNqZ29Scy1jQmhXMzlMbHV3bjJZaVhsYTg4dGNXalVhczBiU3BSUjRfcGlXQ2E3MU80TnJpSmFNZ0llU1FUWl9kOFhBQUsxRTdkT2pCcHVRcXZUWTN0c3FzRGdzeVVyR1BMNHJhXzhUbGgyWE8tVmdNeVdvSE1peUg0UC1qNmhwUQ?oc=5","date":"2026-03-23","type":"trial","source":"AD HOC NEWS","summary":"NexImmune Inc stock faces renewed scrutiny amid clinical trial updates and biotech sector volatility - AD HOC NEWS","headline":"NexImmune Inc stock faces renewed scrutiny amid clinical trial updates and biotech sector volatility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNd1l0a3RRc0FMZkxCQ2lJVVFCT29pWkVQSllpRVRyOWxtNU94cWZla29tNTB1bUlvSGNjVHVTQU43by0yUmhVbFhZUDNjY0FPbWRLMnQtRFFTRDA2MDJjS2tlX0pFS2xFdlRTTWUwZGluU1FNVVRGZnduVFZ6My1vTDg1a3diOTFSMGhGbDdqd25GS0NzYmJJTDFKd0tpc3BLclBxTmhDeEE0eHdlSGI0aERNQzJ4ekFuVjZ2eFZIbXBZR2ZHYWc?oc=5","date":"2026-03-21","type":"pipeline","source":"AD HOC NEWS","summary":"NexImmune Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS","headline":"NexImmune Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQUWZQenZqWkxQcnJvZklSRGNCSXNYQWVMWTJRUVVZZm1JQ0ljcHZYRC1KeTJTaWhQTVFrOW9xc3paVkw3N0NYNEJqUnVqck9ZU1BwRzE3WTQ5RzQ2TnlVUnVVZnJaR3dDWHU0V1FrX0gxekVJY3RUMEpnWm1vU3ZZTldBb2UzR0EtTkJrZE5WVlhra09OOGJFeTJLTlFkSzlaY1BKbWd5NVhYc1pvdWNiN19RVFA5TmdqYWFvTkRYYw?oc=5","date":"2026-03-16","type":"pipeline","source":"AD HOC NEWS","summary":"NexImmune Inc Stock (ISIN: US65343B1044): Immunotherapy Play Eyes Clinic Expansion Amid Biotech Vola - AD HOC NEWS","headline":"NexImmune Inc Stock (ISIN: US65343B1044): Immunotherapy Play Eyes Clinic Expansion Amid Biotech Vola","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNWDJjOFVpTlF6aFAtdzJaQnhleEptanI5dm1jZ2U3NkxpUVVMcjdrb0ZQXzRiV3BidlJXSS1QZVQzVEN1Njk1YU1lTGplWmU1RC1EeENhVDJET2FDSVFZNTFiWV9NeFo3YTAyQTRXV3JvbHNTY1EzTzV0Y1FyRFoydHh2RC10Tm9KdVZTNU9SbWM5MXpEdzJ2cG9zd1BMZjJ1VGpNeS0tWHJWOGpXelRialV5cmhydTFicXNoWmxLSTh2b1ltWVJGTm1OaXE3YVF6dksxeHNvbGNtalhLXzFidFVGZ2MwSkJF?oc=5","date":"2025-04-08","type":"pipeline","source":"PR Newswire","summary":"TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - PR Newswire","headline":"TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYWNjbGphNTNGRWRURXItQWJySjZBRzRBa2tfUWNuT1JTajJFMVo1Ykd0MUd3dXBjdmNzcV9PZGx6dWtsZlNsa1VTbER3R18wdndLVEFwTy1pNWRyYXJHdzY3UkM5VWdSaXJtQVlXZzRWNzJka2w5ZzV6RU5pR1MyemhLaS1vX2pfRHp6UFlMSkZtRllzblNfeTFEOTNZa21jYnNVZDBIekV0MnM?oc=5","date":"2024-10-03","type":"pipeline","source":"BioSpace","summary":"Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033 - BioSpace","headline":"Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQSWc3dkFXTXBNekVIVlVQR2pPa3ptOVhvLTVSNlRpNjNuOE9jbUVxQlMxYUdaZTQ3TnI3QWt2UG01OU9Uamk5czNSc1ppdVpJQWZRMVJQMWt6QVU0aDlSSEZJZUIweE5RMG5SOGJCdW5qdHZlN3gxTUJ6MUpuU0djQzVqTENjZU5XZlY3NGVNajBtRlBBdVdJQXI1TW4?oc=5","date":"2024-08-30","type":"pipeline","source":"The Business Journals","summary":"NexImmune moves forward with wind-down process - The Business Journals","headline":"NexImmune moves forward with wind-down process","sentiment":"neutral"},{"date":"2024-08-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcDdJQkU0eXFCNUZwY19KRVVVOGFJN0pITHRwdC0td2tXQm1zVDBhNzNDLVNUTHdJcUVtSEo2Sy1aZUtvb09ZSDZ1VDdCeVV2V2FSbmFibWVSVl9EVGIzcGJnM3NpVEw3N1FfVG5TaUJPNUFMa3NzNUZMSWd2VnRERHJwa2VTVFJDZWV6dkRjc2dyX1AyUmFLU21uWWxxZEdrUmx1cWdkeUMtWDQ?oc=5","date":"2024-08-15","type":"regulatory","source":"Investing.com","summary":"NexImmune shareholders approve company dissolution - Investing.com","headline":"NexImmune shareholders approve company dissolution","sentiment":"positive"},{"date":"2024-08-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-08-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-08-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-06-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-05-20","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":0,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":19282230,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-32344393,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":3202452,"cashHistory":[],"totalAssets":8593949,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}